Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:CMPS NASDAQ:DYN NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.61-6.5%$11.94$3.98▼$13.68$2.05B1.931.76 million shs1.95 million shsCMPSCOMPASS Pathways$5.20-0.8%$4.36$2.25▼$7.53$502.73M2.171.78 million shs703,769 shsDYNDyne Therapeutics$13.15-0.2%$11.21$6.36▼$37.08$1.87B1.12.20 million shs2.03 million shsTVTXTravere Therapeutics$23.47-6.1%$17.72$12.57▼$28.69$2.09B0.792.57 million shs2.94 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-6.52%-1.87%-3.00%+22.19%+187.24%CMPSCOMPASS Pathways-0.76%+1.17%+21.21%+18.45%-24.09%DYNDyne Therapeutics-0.23%-7.52%+7.43%-8.74%-59.66%TVTXTravere Therapeutics-6.12%+8.46%+30.03%+61.86%+91.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.61-6.5%$11.94$3.98▼$13.68$2.05B1.931.76 million shs1.95 million shsCMPSCOMPASS Pathways$5.20-0.8%$4.36$2.25▼$7.53$502.73M2.171.78 million shs703,769 shsDYNDyne Therapeutics$13.15-0.2%$11.21$6.36▼$37.08$1.87B1.12.20 million shs2.03 million shsTVTXTravere Therapeutics$23.47-6.1%$17.72$12.57▼$28.69$2.09B0.792.57 million shs2.94 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-6.52%-1.87%-3.00%+22.19%+187.24%CMPSCOMPASS Pathways-0.76%+1.17%+21.21%+18.45%-24.09%DYNDyne Therapeutics-0.23%-7.52%+7.43%-8.74%-59.66%TVTXTravere Therapeutics-6.12%+8.46%+30.03%+61.86%+91.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.88Moderate Buy$12.38-1.86% DownsideCMPSCOMPASS Pathways 2.86Moderate Buy$16.29213.19% UpsideDYNDyne Therapeutics 3.06Buy$34.07159.06% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$34.2045.72% UpsideCurrent Analyst Ratings BreakdownLatest CMPS, ADPT, DYN, and TVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025TVTXTravere TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$20.00 ➝ $25.009/11/2025TVTXTravere TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$27.00 ➝ $35.009/10/2025TVTXTravere TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.009/10/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.009/3/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.008/28/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $47.008/25/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$31.00 ➝ $35.008/10/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/7/2025TVTXTravere TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/7/2025TVTXTravere TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$30.00 ➝ $31.008/7/2025TVTXTravere TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$30.00 ➝ $32.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$205.22M9.36N/AN/A$1.37 per share9.20CMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/ADYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/ATVTXTravere Therapeutics$333.87M6.27N/AN/A$0.76 per share30.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.82N/AN/AN/A-59.07%-60.93%-23.03%11/6/2025 (Estimated)CMPSCOMPASS Pathways-$155.12M-$1.84N/AN/AN/AN/A-87.89%-57.77%10/30/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)TVTXTravere Therapeutics-$321.55M-$2.04N/AN/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)Latest CMPS, ADPT, DYN, and TVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025TVTXTravere Therapeutics-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 million8/5/2025Q2 2025ADPTAdaptive Biotechnologies-$0.24-$0.17+$0.07-$0.17$49.40 million$49.94 million7/31/2025Q2 2025CMPSCOMPASS Pathways-$0.37-$0.38-$0.01-$0.41N/AN/A7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.842.75CMPSCOMPASS Pathways0.168.828.82DYNDyne Therapeutics0.1716.8316.83TVTXTravere Therapeutics9.502.001.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%CMPSCOMPASS Pathways46.19%DYNDyne Therapeutics96.68%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%CMPSCOMPASS Pathways3.93%DYNDyne Therapeutics14.14%TVTXTravere Therapeutics4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790152.27 million142.53 millionOptionableCMPSCOMPASS Pathways12095.94 million92.17 millionOptionableDYNDyne Therapeutics100142.26 million122.15 millionOptionableTVTXTravere Therapeutics46089.14 million85.40 millionOptionableCMPS, ADPT, DYN, and TVTX HeadlinesRecent News About These CompaniesTravere Therapeutics (NASDAQ:TVTX) Shares Down 4.8% - Should You Sell?September 13 at 2:11 PM | marketbeat.comWells Fargo & Company Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00September 13 at 8:51 AM | marketbeat.comWoodline Partners LP Sells 884,278 Shares of Travere Therapeutics, Inc. $TVTXSeptember 13 at 4:36 AM | marketbeat.comWells Fargo & Company Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00September 13 at 3:25 AM | americanbankingnews.comTravere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGSSeptember 12 at 4:08 PM | seekingalpha.comHC Wainwright Reaffirms Buy Rating for Travere Therapeutics (NASDAQ:TVTX)September 12 at 1:19 PM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year High - Here's What HappenedSeptember 12 at 10:22 AM | marketbeat.comTVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDASeptember 11 at 11:40 AM | zacks.comTravere Therapeutics price target raised to $35 from $27 at Wells FargoSeptember 11 at 10:22 AM | msn.comTravere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate SubsideSeptember 11 at 10:10 AM | insidermonkey.comStrength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?September 11 at 6:01 AM | zacks.comTravere rises as FDA says no AdCom required for Filspari label expansionSeptember 10 at 5:13 PM | msn.comTravere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug ApplicationSeptember 10 at 5:13 PM | msn.comTravere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical ResultsSeptember 10 at 5:13 PM | finance.yahoo.comTravere: No AdCom, No Problem - Targeting Big Revenues With FSGS ApprovalSeptember 10 at 3:03 PM | seekingalpha.comTraders Purchase High Volume of Call Options on Travere Therapeutics (NASDAQ:TVTX)September 10 at 1:20 PM | marketbeat.comWhy Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year HighSeptember 10 at 9:13 AM | investors.comTravere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGSSeptember 10 at 7:01 AM | businesswire.comPolar Asset Management Partners Inc. Acquires New Position in Travere Therapeutics, Inc. $TVTXSeptember 9, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Reduces Stock Position in Travere Therapeutics, Inc. $TVTXSeptember 9, 2025 | marketbeat.comTravere Therapeutics Sees Unusually High Options Volume (NASDAQ:TVTX)September 9, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPS, ADPT, DYN, and TVTX Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$12.61 -0.88 (-6.52%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$12.90 +0.29 (+2.27%) As of 09/12/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.COMPASS Pathways NASDAQ:CMPS$5.20 -0.04 (-0.76%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.20 0.00 (0.00%) As of 09/12/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Dyne Therapeutics NASDAQ:DYN$13.15 -0.03 (-0.23%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$13.14 -0.01 (-0.04%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Travere Therapeutics NASDAQ:TVTX$23.47 -1.53 (-6.12%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$23.40 -0.07 (-0.32%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
